Change in number of shares and votes in Alligator Bioscience

During the month of December, the number of shares and votes in Alligator Bioscience AB has changed due to conversion of a total of 170,681 series C shares into a total of 170,681 ordinary shares for delivery of shares to participants in the performance-based share saving program that was adopted by the annual general meeting held on 1 June 2021 (LTI 2021).

As of 30 December 2024, the number of shares in Alligator Bioscience AB amounts to 758,989,086 shares, of which 758,209,917 are ordinary shares with one vote each and 779,169 are series C shares with 1/10 vote each. The total number of votes in the company amounts to 758,287,833.9.

About Alligator Bioscience

Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. Its portfolio includes lead drug candidate mitazalimab, for which the company reported unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in Phase 2 testing and is in preparation for Phase 3 development. The follow-on bispecific antibody ATOR-4066 is in preclinical testing. Alligator has a proprietary technology platform, comprised of two antibody libraries, ALLIGATOR-GOLD® and ALLIGATOR-FAB™, the powerful protein optimization strategy FIND® and the bispecific antibody format RUBY™, which drives rapid design and development of innovative drugs.

Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Categorized as